ATE491467T1 - Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans - Google Patents

Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans

Info

Publication number
ATE491467T1
ATE491467T1 AT05747432T AT05747432T ATE491467T1 AT E491467 T1 ATE491467 T1 AT E491467T1 AT 05747432 T AT05747432 T AT 05747432T AT 05747432 T AT05747432 T AT 05747432T AT E491467 T1 ATE491467 T1 AT E491467T1
Authority
AT
Austria
Prior art keywords
compositions containing
vaccine compositions
saponin adjuvant
virosome
provides
Prior art date
Application number
AT05747432T
Other languages
English (en)
Inventor
Beth-Ann Coller
Veronique Henderickx
Nathalie M J Garcon
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35045004&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE491467(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0412039.0A external-priority patent/GB0412039D0/en
Priority claimed from GB0412304A external-priority patent/GB0412304D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Application granted granted Critical
Publication of ATE491467T1 publication Critical patent/ATE491467T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT05747432T 2004-05-28 2005-05-26 Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans ATE491467T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0412039.0A GB0412039D0 (en) 2004-05-28 2004-05-28 Compositions
GB0412304A GB0412304D0 (en) 2004-06-02 2004-06-02 Compositions
PCT/EP2005/005786 WO2005117958A1 (en) 2004-05-28 2005-05-26 Vaccine compositions comprising virosomes and a saponin adjuvant

Publications (1)

Publication Number Publication Date
ATE491467T1 true ATE491467T1 (de) 2011-01-15

Family

ID=35045004

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05747432T ATE491467T1 (de) 2004-05-28 2005-05-26 Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans

Country Status (8)

Country Link
US (1) US20090263470A1 (de)
EP (2) EP2269638A3 (de)
JP (1) JP2008500984A (de)
AT (1) ATE491467T1 (de)
AU (2) AU2005249212B2 (de)
CA (1) CA2565500A1 (de)
DE (1) DE602005025342D1 (de)
WO (1) WO2005117958A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
NZ568212A (en) * 2005-11-04 2012-03-30 Novartis Vaccines & Diagnostic Changing Th1/Th2 balance in split influenza vaccines with adjuvants
CA2628152C (en) 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
KR20100045413A (ko) * 2007-06-14 2010-05-03 크루셀 스위츨랜드 아게 피내 인플루엔자 백신
EP2058002A1 (de) * 2007-10-31 2009-05-13 Bestewil Holding B.V. Rekonstituierte Virushüllen des Respiratory Syncytial Virus und Anwendung als Impfstoff für Respiratory Syncytial Virus
RS53347B (sr) 2008-12-09 2014-10-31 Gilead Sciences, Inc. Modulatori toll-sličnih receptora
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
EP3173097A3 (de) 2009-02-10 2017-07-12 Seqirus UK Limited Influenzaimpfstoffe mit reduzierten anteilen an squalen
JP5854559B2 (ja) 2009-07-06 2016-02-09 ヴァリエーション バイオテクノロジーズ インコーポレイテッド 小胞を調製する方法及びこれから製造される製剤
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
CA3150411C (en) 2009-07-31 2023-09-12 Pnuvax Inc. High yield yellow fever virus strain with increased propagation in cells
CA2772253C (en) 2009-09-14 2018-02-27 Gilead Sciences, Inc. Modulators of toll-like receptors
JP5774010B2 (ja) * 2009-09-25 2015-09-02 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム インフルエンザウイルスのための免疫拡散アッセイ
JP2013525431A (ja) * 2010-04-30 2013-06-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 合成ｔｌｒ７アゴニストのリン脂質結合体の使用
WO2012006367A2 (en) * 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
EP2595653B1 (de) * 2010-07-23 2017-06-28 Novavax AB Influenza-impfstoff
AR079970A1 (es) * 2010-07-23 2012-02-29 Xcellerex Inc Cepas de alto rendimiento del virus de la fiebre amarilla con una propagacion incrementada en las celulas
CN102078606B (zh) * 2010-12-08 2014-12-31 中国人民解放军军事医学科学院微生物流行病研究所 一种呼吸道合胞病毒体疫苗及其制备方法
CN102107003A (zh) * 2011-01-05 2011-06-29 重庆大学 一种猪繁殖与呼吸综合症病毒体疫苗及其制备方法
US10736844B2 (en) 2011-01-13 2020-08-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
AU2013208693B2 (en) 2012-01-12 2017-12-07 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
EP2806894A4 (de) 2012-01-27 2015-11-04 Variation Biotechnologies Inc Verfahren und zusammensetzungen für therapeutika
EP4218808A3 (de) * 2012-03-12 2023-08-09 Advanced BioAdjuvants, LLC Adjuvans- und impfstoffzusammensetzungen
WO2015000831A1 (en) 2013-07-02 2015-01-08 Crucell Holland B.V. Method for preparing virosomes
WO2015000832A1 (en) 2013-07-02 2015-01-08 Crucell Holland B.V. Method for preparing virosomes
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
JP6522732B2 (ja) 2014-07-11 2019-05-29 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖを治療するためのトール様受容体の調節因子
WO2016039620A2 (en) * 2014-09-12 2016-03-17 Bestewil Holding B.V. Respiratory syncytial virus virosomes
WO2016039619A1 (en) * 2014-09-12 2016-03-17 Bestewil Holding B.V. Methods for providing adjuvanted virosomes and adjuvanted virosomes obtainable thereby
KR102306860B1 (ko) 2014-09-16 2021-09-30 길리애드 사이언시즈, 인코포레이티드 톨-유사 수용체 조정제를 제조하는 방법
SG11201701520TA (en) 2014-09-16 2017-04-27 Gilead Sciences Inc Solid forms of a toll-like receptor modulator
CN104488927A (zh) * 2014-12-03 2015-04-08 广东中迅农科股份有限公司 一种含有甾烯醇和螺虫乙酯的农药组合物
BR112018007870A2 (pt) 2015-10-19 2019-01-15 Cadila Healthcare Ltd composição imunogênica, método para a preparação de uma composição imunogênica, composição farmacêutica, vacina, método para estimular uma resposta imune em um paciente
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
US11523988B2 (en) 2018-11-29 2022-12-13 Catalent U.K. Swindon Zydis Limited Oral dispersible vaccine comprising virosomes
TWI810456B (zh) 2019-05-22 2023-08-01 美商基利科學股份有限公司 Tlr7調節化合物及hiv疫苗之組合
CN110302373A (zh) * 2019-07-01 2019-10-08 大连民族大学 利用跨膜区定向排列病毒包膜蛋白疫苗及其制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3238190A (en) 1963-10-23 1966-03-01 Madaus & Co K G Fa Dr Aescin recovery
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
EP0362278A4 (de) 1987-06-05 1990-05-14 Us Health Autokrine beweglichkeitsfaktoren bei der diagnose und behandlung von krebs.
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
PL181241B1 (pl) 1993-11-17 2001-06-29 Deutsche Om Arzneimittel Gmbh Disacharydy beta(1 6)glukozoaminowe, sposób wytwarzania disacharydu beta(1 6) glukozoaminowego, zawierająca je kompozycja farmaceutyczna i środek immunomodulujący i/lub przeciwnowotworowy oraz szczepionka
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
WO1998056415A1 (en) 1997-06-11 1998-12-17 Aquila Biopharmaceuticals, Inc. Purified saponins as oral adjuvants
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
CA2302522C (en) 1997-08-29 2010-08-17 Antigenics Llc Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
AU7924598A (en) 1998-06-08 1999-12-30 Sca Emballage France Fast flattening packaging
CN1168702C (zh) 1998-06-30 2004-09-29 Om药业 酰基-二肽类化合物,其制备方法以及含有前述化合物的药物组合物
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
PT1104306E (pt) 1998-08-10 2006-05-31 Antigenics Inc Composicoes de cpg e adjuvantes de saponina e seus metodos
PT1187629E (pt) 1999-04-19 2005-02-28 Glaxosmithkline Biolog Sa Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
WO2001046127A1 (fr) 1999-12-22 2001-06-28 Om Pharma Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise
GB0123580D0 (en) * 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
NZ536859A (en) * 2002-05-14 2007-11-30 Chiron Srl Mucosal combination vaccines for bacterial meningitis
KR20050010040A (ko) * 2002-06-11 2005-01-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
GB0218921D0 (en) * 2002-08-14 2002-09-25 Glaxosmithkline Biolog Sa Novel vaccine

Also Published As

Publication number Publication date
US20090263470A1 (en) 2009-10-22
CA2565500A1 (en) 2005-12-15
EP2269638A3 (de) 2012-06-13
EP2269638A2 (de) 2011-01-05
DE602005025342D1 (de) 2011-01-27
AU2005249212A1 (en) 2005-12-15
EP1755666B1 (de) 2010-12-15
JP2008500984A (ja) 2008-01-17
AU2005249212B2 (en) 2010-05-20
AU2010202974A1 (en) 2010-08-05
EP1755666A1 (de) 2007-02-28
WO2005117958A1 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
ATE491467T1 (de) Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
NO20021431L (no) Intranasal influensavirus vaksine
ATE503493T1 (de) Influenza vakzinzusammensetzungen zur intradermaler verabreichung
ATE331530T1 (de) Proteasom-influenzavirus-impfstoffzusammensetzu g
WO2006113214A3 (en) Vaccine against pandemic strains of influenza viruses
WO2004112831A3 (en) High titer recombinant influenza viruses for vaccines and gene therapy
WO2007068907A3 (en) Vaccine compositions comprising a saponin adjuvant
EP1326633A4 (de) Zusammensetzung mit immunogenen mikroteilchen
WO2002087494A3 (en) Novel vaccine
WO2005105139A3 (en) Mage-3 and ny-eso-1 based polyvalent vaccine for cancer immunotherapy
EP2290091A3 (de) Rekombinante Masernviren, welche Epitope der Antigene von RNA-Viren exprimieren, sowie die Verwendung der rekombinanten Viren zur Herstellung von Impfstoffen
CY1110744T1 (el) Ανοσοδιεγερτικος συνδυασμος για την προφυλακτικη και θεραπευτικη αντιμετωπιση της ηπατιτιδας c
WO2007052165A3 (en) A lentiviral vector-based vaccine
WO2007052059A3 (en) Changing th1/th2 balance in split influenza vaccines with adjuvants
EA200801251A1 (ru) Вакцины против гриппа, адсорбированные на алюминиевых адъювантах, для немедленного приёма
WO2005120564A3 (en) Vaccine compositions and methods
WO2004045641A3 (en) Antigen-complexes
DE60036705D1 (de) Adjuvanskombinationen zur immunisierung und vakzine
WO2007028985A3 (en) Adjuvanted vaccine
ITRM20040066A1 (it) Metodo di identificazione di peptidi antigenici e relativo uso per la preparazione di un vaccino anti hiv-1.
IL193391A0 (en) Influenza antigens, vaccine compositions, and related methods
EP1721618A3 (de) Proteasom-influenzavirus-impfstoffzusammensetzung
RU2004130267A (ru) Способ вакцинации детей против краснухи на крайнем севере
CY1114467T1 (el) Μικρορευστοποιημενα γαλακτωματα ελαιου-σε-νερο και συνθεσεις εμβολιου

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties